Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Notes Establishment of Multidistrict Litigation For Federal Lawsuits Involving Byetta, Similar Diabetes Drugs

New York, New York (PRWEB) August 27, 2013

Byetta lawsuits (, as well as all other federally-filed product liability claims involving the incretin mimetic class of diabetes drugs, have been transferred to the U.S. District Court, Southern District of California, for pretrial proceedings, Bernstein Liebhard LLP reports. According to a Transfer Order issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on August 26, 2013, the consolidated proceeding will be presided over by the Honorable Anthony J. Battaglia. All of the claims pending in the newly-established multidistrict litigation involve allegations of a possible association between incretin mimetics, including Byetta, and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous inquiries from patients who used Byetta and other diabetes drugs in this class, and who are concerned that these medications resulted in their pancreatic cancer diagnosis. We agree that a consolidated proceeding will provide an efficient means of resolving claims involving incretin mimetics, including Byetta lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Byetta pancreatic cancer, as well as pancreatitis and thyroid cancer.

Byetta and Pancreatic Cancer
Byetta and other incretin mimetics work to regulate insulin production in the pancreas by mimicking the action of incretin, a hormone produced in the intestinal tract. However, since its launch in 2005, the U.S. Food & Drug Administration (FDA) has released a number of Byetta warnings regarding the medication’s potentially harmful effects on the pancreas. In 2008, for example, the agency revealed that Byetta had been associated with a high number of adverse event reports involving pancreatitis.* Concerns about Byetta and pancreatic cancer were heightened after March 14, 2013, when the FDA announced it was investigating findings from an unpublished study that suggested drugs like Byetta could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.

In April 2013, the Institute for Safe Medicine Practices reported that incretin mimetics like Byetta were 25 times more likely to be associated with reports of pancreatic cancer compared to other classes of diabetes medications. According to the group, its analysis of FDA adverse event reports recorded during the 12 month period that ended in June 2012 also revealed that Byetta had been associated with 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer.** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***

Court documents indicate that at least 53 lawsuits have been filed on behalf of patients who developed pancreatic cancer, allegedly due to their use of Byetta and other incretin mimetics. A multidistrict litigation, such as the one established for these claims, consolidates all lawsuits involving common questions of fact in one jurisdiction for coordinated pretrial proceedings. The aim of a multidistrict litigation is to avoid duplicative discovery and inconsistent rulings across similar claims, and to conserve the resources of the court, parties and witnesses.

Alleged victims of Byetta and pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills and other damages. Learn More about the possible link between Byetta and pancreatic cancer at Bernstein Liebhard LLP’s website. For a free Byetta lawsuit review, please call 800-511-5092.

*, FDA, August 18, 2008
**, ISMP, April 2013
***; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Federal Judicial Panel Considering Byetta Lawsuit Consolidation, Rottenstein Law Group LLP Reports
2. Byetta Pancreatic Cancer Allegation Lawsuits Update: Resource4thePeople Awaiting Federal Court Decision on Possible Creation of Multidistrict Litigation
3. Byetta Lawsuit Investigation Being Conducted by Bernstein Liebhard LLP On Behalf of Byetta Users Diagnosed with Pancreatic Cancer, Pancreatitis, and Thyroid Cancer
4. Byetta Lawsuit - Claims Move Forward, as Panel Considers Consolidation of Federal Claims Involving Byetta and Similar Diabetes Drugs, Bernstein Liebhard LLP Reports
5. Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims
6. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
7. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
8. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
9. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
10. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
11. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Autism Speaks, ... the global movement driven by social media and the generosity of people around the ... encourage their social media networks to give – and share the personal stories behind ...
(Date:11/24/2015)... Tennessee (PRWEB) , ... November 24, 2015 , ... ... Pharmacy Quality Trend Report . Throughout the past year there have been multiple breakthroughs ... mature state. During this transition, PharmMD has enabled their customers and partners to stay ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... “I am so thrilled, as a newbie ... after learning she had won a $7,500 School Lounge Makeover® from California Casualty . ... most of the staff has a much longer tenure. , “This is such an amazing ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
(Date:11/24/2015)... BERN, Switzerland , November 24, 2015 ... for Biomedical Engineering Research of the University of ... Endocrinology, Diabetes and Clinical Nutrition of the Bern University ... an exclusive collaboration to develop a novel generation artificial ... personalised delivery of insulin for diabetic patients with the ...
(Date:11/24/2015)... 2015 st  Scientific Assembly and Annual Meeting ... (RSNA) taking place in Chicago on Nov-29 ... --> st  Scientific Assembly and Annual Meeting of the ... place in Chicago on Nov-29 th ... Molecular Dynamics will present its revolutionary whole body CZT digital ...
Breaking Medicine Technology: